Literature DB >> 1713689

Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction.

J P Bader1, J B McMahon, R J Schultz, V L Narayanan, J B Pierce, W A Harrison, O S Weislow, C F Midelfort, S F Stinson, M R Boyd.   

Abstract

Oxathiin carboxanilide (OC), NSC 615985, a compound originally synthesized as a potential fungicide, was demonstrated to be highly active in preventing human immunodeficiency virus (HIV)-induced cell killing and in inhibiting HIV reproduction. Virus-infected CD4+ lymphocytes were completely protected by 0.5 microM OC, whereas no toxicity was observed at concentrations below 50 microM OC. Production of infectious virus, viral p24 antigen, and virion reverse transcriptase were reduced by OC at concentrations that prevented viral cell killing. A variety of CD4+ T-cell lines were protected by OC from HIV cytopathicity, and OC inhibited two distinct strains of HIV-1. However, HIV-2 infections were unaffected by OC. OC had no direct effect on virions of HIV or on the enzymatic activities of HIV reverse transcriptase or HIV protease. Time-limited treatments of cells with OC before, during, or after exposure of cells to virus failed to protect cells from the eventual cytopathic effects of HIV, and OC failed to inhibit the production of virus from cells in which infection was established or from chronically infected cells. We conclude that the highly active OC has a reversible effect on some early stage of HIV-1 reproduction and cytopathicity. Pilot in vivo experiments showed that circulating concentrations of OC exceeding 1 microM could be achieved and sustained in hamsters for at least a week with no remarkable toxicological sequelae. OC represents a new class of anti-HIV agents that are promising candidates for drug development.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713689      PMCID: PMC52164          DOI: 10.1073/pnas.88.15.6740

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  THE REQUIREMENT FOR DNA SYNTHESIS IN THE GROWTH OF ROUS SARCOMA AND ROUS-ASSOCIATED VIRUSES.

Authors:  J P BADER
Journal:  Virology       Date:  1965-06       Impact factor: 3.616

Review 2.  Development of antiviral drugs for the treatment of AIDS: strategies and prospects.

Authors:  W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

3.  Chemical synthesis and expression of the HIV-1 protease gene in E. coli.

Authors:  J M Louis; E M Wondrak; T D Copeland; C A Smith; P T Mora; S Oroszlan
Journal:  Biochem Biophys Res Commun       Date:  1989-02-28       Impact factor: 3.575

4.  The HIV 'A' (sor) gene product is essential for virus infectivity.

Authors:  K Strebel; D Daugherty; K Clouse; D Cohen; T Folks; M A Martin
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

5.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; D L Cannon; B H Arnold; D Martino-Saltzman
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

6.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

7.  Acute glomerulonephritis and skin sepsis.

Authors: 
Journal:  Lancet       Date:  1968-03-16       Impact factor: 79.321

8.  Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.

Authors:  G Ahluwalia; D A Cooney; H Mitsuya; A Fridland; K P Flora; Z Hao; M Dalal; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1987-11-15       Impact factor: 5.858

9.  Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

Authors:  M Matsukura; G Zon; K Shinozuka; M Robert-Guroff; T Shimada; C A Stein; H Mitsuya; F Wong-Staal; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

10.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

View more
  17 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus.

Authors:  J Balzarini; W G Brouwer; D C Dao; E M Osika; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.

Authors:  R W Buckheit; E L White; V Fliakas-Boltz; J Russell; T L Stup; T L Kinjerski; M C Osterling; A Weigand; J P Bader
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.

Authors:  G Borkow; J Barnard; T M Nguyen; A Belmonte; M A Wainberg; M A Parniak
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.

Authors:  M Witvrouw; M E Arranz; C Pannecouque; R Declercq; H Jonckheere; J C Schmit; A M Vandamme; J A Diaz; S T Ingate; J Desmyter; R Esnouf; L Van Meervelt; S Vega; J Balzarini; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription.

Authors:  J A Turpin; R W Buckheit; D Derse; M Hollingshead; K Williamson; C Palamone; M C Osterling; S A Hill; L Graham; C A Schaeffer; M Bu; M Huang; W M Cholody; C J Michejda; W G Rice
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.

Authors:  Charlene S Dezzutti; V Nicole James; Artur Ramos; Sharon T Sullivan; Aladin Siddig; Timothy J Bush; Lisa A Grohskopf; Lynn Paxton; Shambavi Subbarao; Clyde E Hart
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781.

Authors:  Haitao Yang; Michael A Parniak; Charles E Isaacs; Sharon L Hillier; Lisa C Rohan
Journal:  AAPS J       Date:  2008-12-17       Impact factor: 4.009

9.  T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.

Authors:  J O Ojwang; R W Buckheit; Y Pommier; A Mazumder; K De Vreese; J A Esté; D Reymen; L A Pallansch; C Lackman-Smith; T L Wallace
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.

Authors:  R W Buckheit; T L Kinjerski; V Fliakas-Boltz; J D Russell; T L Stup; L A Pallansch; W G Brouwer; D C Dao; W A Harrison; R J Schultz
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.